Arctic Vision Acquires MDCO Technology's Ophthalmic Device Business to Create Integrated Drug-Device Platform
核心洞察
Arctic Vision (搜索) announced the acquisition of MDCO Technology (搜索)'s ophthalmic device business, integrating premium intraocular lens and implantable contact lens platforms with Arctic Vision's pharmaceutical capabilities.
The transaction creates a comprehensive ophthalmic innovation ecosystem combining Arctic Vision (搜索)'s R&D expertise in retinal, ocular surface, and neuro-ophthalmic areas with MDCO's device manufacturing capabilities.
MDCO will become a wholly owned subsidiary while maintaining operations across Shanghai, Hangzhou, and California to accelerate global development and market access for ophthalmic therapeutics.
Arctic Vision (搜索) (Cayman) Limited, a Shanghai-headquartered global ophthalmic company, announced on February 2, 2026, that it has entered into an agreement to acquire the innovative ophthalmic device business of MDCO Technology (搜索), a Hangzhou-based ophthalmic medical-device company. The strategic acquisition aims to create an integrated drug-device innovation platform addressing high unmet needs in ophthalmology.
Strategic Integration of Device and Drug Platforms
The proposed transaction will bring MDCO's premium intraocular lens (IOL), implantable contact lens (Phakic Lens), and refractive-device platforms into Arctic Vision (搜索)'s global ophthalmic innovation framework. This integration strengthens Arctic Vision's global ophthalmic business by combining advanced device engineering and intelligent manufacturing with its existing pharmaceutical innovation capabilities.
The transaction is expected to create an industry-leading pipeline, building on Arctic Vision (搜索)'s deep R&D capabilities in retinal, ocular surface, and neuro-ophthalmic areas, together with MDCO's design and manufacturing expertise in IOL and Phakic Lens technologies.
Operational Structure and Geographic Footprint
Under the terms of the transaction, MDCO will become a wholly owned subsidiary of Arctic Vision (搜索). The combined group will maintain key operations across three strategic locations: Shanghai for biopharmaceutical R&D, regulatory affairs, and operations; Hangzhou for implanted device R&D, manufacturing, and commercial management; and California for design and global collaboration.
MDCO Technology (搜索) specializes in intraocular and refractive lens systems, with R&D and manufacturing bases in Hangzhou, China and California, U.S. The company has nearly two decades of materials-science and precision-molding expertise, focusing on premium cataract (搜索) and myopia (搜索)-correction solutions with recognized capabilities in intelligent manufacturing and surgical-platform innovation.
Leadership Vision for Global Expansion
"This transaction represents a pivotal step for Arctic Vision (搜索)'s long-term growth strategy," said Dr. Eddy Wu, Founder, Chairman and CEO of Arctic Vision. "Through the integration of MDCO's ophthalmic device platforms with Arctic Vision's pharmaceutical innovation capabilities, we are establishing a truly comprehensive ophthalmic innovation ecosystem—one that integrates scientific excellence with advanced manufacturing and commercial scale."
Dr. Wu emphasized the strategic positioning for future growth: "Looking ahead, we are building a company structurally prepared for broader global investment participation and future capital-market opportunities, while expanding our ability to reach more patients and deliver greater impact across the ophthalmology community worldwide."
Mr. Liang Liu, Chairman of MDCO Technology (搜索), highlighted the benefits of the integration: "Becoming part of Arctic Vision (搜索)'s integrated platform opens a new chapter for MDCO. MDCO's hallmark intraocular and refractive products will benefit from Arctic Vision's strong R&D and regulatory foundation, enabling accelerated development and broader market access worldwide."
Comprehensive Ophthalmic Innovation Ecosystem
Arctic Vision (搜索) is committed to developing and commercializing next-generation ophthalmic therapies in retinal disease (搜索), dry eye (搜索), and ocular neuroprotection. With global operations spanning Hong Kong and the U.S., the company leverages an in-house platform and strategic partnerships to drive innovation from pre-clinical discovery through commercialization.
The proposed transaction aligns with Arctic Vision (搜索)'s long-term strategy of expanding the company's pipeline with innovative therapeutics addressing high unmet medical needs in ophthalmology. The integration is designed to accelerate ophthalmic innovation globally across both drug and device platforms, creating synergies between pharmaceutical development and advanced medical device manufacturing.